查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
钙通道阻断剂市场 - 2023-2031年全球行业分析、规模、份额、增长、趋势和预测
市场调查报告书
商品编码
1301438

钙通道阻断剂市场 - 2023-2031年全球行业分析、规模、份额、增长、趋势和预测

Calcium Channel Blockers Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 185 Pages | 商品交期: 2-10个工作天内

价格

钙通道阻断剂市场 - 报告范围

TMR关于全球钙通道阻断剂市场的报告研究了过去以及当前的增长趋势和机会，以便在2023年至2031年的预测期间获得对市场指标的宝贵见解。报告提供了2017-2031年期间全球钙通道阻断剂市场的收入，考虑到2023年为基准年，2031年为预测年。报告还提供了2023年至2031年全球钙通道阻断剂市场的复合年增长率（CAGR %）。

该报告是在广泛的研究后编写的。一级研究涉及大部分的研究工作，其中分析师与关键意见领袖、行业领袖和意见制造者进行了访谈。二级研究包括参考主要参与者的产品资料、年度报告、新闻稿和相关文件，以了解钙通道阻断剂市场。

报告深入研究了全球钙通道阻断剂市场的竞争格局。在全球钙通道阻断剂市场运作的主要参与者已被确定，其中每一个都在各种属性方面进行了分析。公司概况、财务状况、近期发展和SWOT是本报告对全球钙通道阻断剂市场参与者的属性描述。

目录

第一章：前言

  • 市场定义和范围
  • 市场细分
  • 主要研究目标
  • 研究重点

第二章：假设和研究方法

第三章：执行摘要：全球市场

第四章：市场概述

  • 简介
    • 定义
    • 行业演变/发展
  • 概述
  • 市场动态
    • 驱动力
    • 限制因素
    • 机会
  • 2017-2031年全球市场分析和预测
    • 市场收入预测

第5章：关键洞察力

  • 全球及主要国家的疾病流行率和发病率
  • 主要产品/品牌分析
  • 管线分析
  • COVID-19大流行对行业的影响

第六章：全球市场分析和预测：按药物类别分类

  • 介绍和定义
  • 主要研究结果/发展情况
  • 市场价值预测：按药物类别，2017-2031年
    • 苯基烷基胺
    • 苯妥英
    • 二氢吡啶
      • 第一代
      • 第二代
      • 第三代
  • 市场吸引力分析：按药物类别

第7章 ：全球市场分析和预测：按应用分类

  • 介绍和定义
  • 主要研究结果/发展情况
  • 市场价值预测：按应用分类，2017-2031年
    • 高血压
    • 心绞痛
    • 心律失常
    • 肥厚型心肌病
    • 其他（雷诺氏病，等）
  • 市场吸引力分析：按应用分类

第八章：全球市场分析与预测：按给药途径分类

  • 介绍和定义
  • 主要研究结果/发展情况
  • 市场价值预测：按给药途径，2017-2031年
    • 口服
    • 肠外
  • 市场吸引力分析：按给药途径分类

第九章：全球市场分析和预测：按分销渠道分类

  • 介绍和定义
  • 主要研究结果/发展情况
  • 市场价值预测：按分销渠道划分，2017-2031年
    • 医院药房
    • 零售药店
    • 网上药店
  • 市场吸引力分析：按分销渠道分类

第十章：全球市场分析与预测：按地区划分

  • 主要研究结果
  • 市场价值预测：按地区
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：按地区

第11章 ：北美洲市场分析与预测

  • 简介
    • 主要研究结果
  • 市场价值预测：按药物类别，2017-2031年
    • 苯基烷基胺
    • 苯硫酚类
    • 二氢吡啶
      • 第一代
      • 第二代
      • 第三代
  • 市场价值预测：按应用分类，2017-2031年
    • 高血压
    • 心绞痛
    • 心律失常
    • 肥厚型心肌病
    • 其他（雷诺氏病等）。
  • 市场价值预测：按给药途径，2017-2031年
    • 口服
    • 肠外
  • 市场价值预测：按分销渠道，2017-2031年
    • 医院药房
    • 零售药店
    • 网上药店
  • 市场价值预测：按国家划分，2017-2031年
    • 美国
    • 加拿大
  • 市场吸引力分析
    • 按药物类别
    • 按应用分类
    • 按给药途径分类
    • 按销售渠道分类
    • 按国家分类

第12章 ：欧洲市场分析和预测

  • 简介
    • 主要发现
  • 市场价值预测：按药物类别，2017-2031年
    • 苯基烷基胺
    • 苯硫酚类
    • 二氢吡啶
      • 第一代
      • 第二代
      • 第三代
  • 市场价值预测：按应用分类，2017-2031年
    • 高血压
    • 心绞痛
    • 心律失常
    • 肥厚型心肌病
    • 其他（雷诺氏病等）。
  • 市场价值预测：按给药途径，2017-2031年
    • 口服
    • 肠外
  • 市场价值预测：按分销渠道，2017-2031年
    • 医院药房
    • 零售药店
    • 网上药店
  • 市场价值预测：按国家/次区域划分，2017-2031年
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 意大利
    • 欧洲其他地区
  • 市场吸引力分析
    • 按药物类别
    • 按应用分类
    • 按给药途径分类
    • 按分销渠道
    • 按国家/次区域分类

第13章 ：亚太地区市场分析和预测

  • 简介
    • 主要发现
  • 市场价值预测：按药物类别，2017-2031年
    • 苯基烷基胺
    • 苯硫酚类
    • 二氢吡啶
      • 第一代
      • 第二代
      • 第三代
  • 市场价值预测：按应用分类，2017-2031年
    • 高血压
    • 心绞痛
    • 心律失常
    • 肥厚型心肌病
    • 其他（雷诺氏病等）。
  • 市场价值预测：按给药途径，2017-2031年
    • 口服
    • 肠外
  • 市场价值预测：按分销渠道，2017-2031年
    • 医院药房
    • 零售药店
    • 网上药店
  • 市场价值预测：按国家/次区域划分，2017-2031年
    • 中国
    • 日本
    • 印度
    • 澳大利亚和新西兰
    • 亚太其他地区
  • 市场吸引力分析
    • 按药物类别
    • 按应用分类
    • 按给药途径
    • 按分销渠道
    • 按国家/次区域分类

第十四章 ：拉美市场分析与预测

  • 简介
    • 主要发现
  • 市场价值预测：按药物类别，2017-2031年
    • 苯基烷基胺
    • 苯硫酚类
    • 二氢吡啶
      • 第一代
      • 第二代
      • 第三代
  • 市场价值预测：按应用分类，2017-2031年
    • 高血压
    • 心绞痛
    • 心律失常
    • 肥厚型心肌病
    • 其他（雷诺氏病等）。
  • 市场价值预测：按给药途径，2017-2031年
    • 口服
    • 肠外
  • 市场价值预测：按分销渠道，2017-2031年
    • 医院药房
    • 零售药店
    • 网上药店
  • 市场价值预测：按国家/次区域划分，2017-2031年
    • 巴西
    • 墨西哥
    • 拉美其他地区
  • 市场吸引力分析
    • 按药物类别
    • 按应用分类
    • 按给药途径分类
    • 按分销渠道
    • 按国家/次区域分类

第15章 ：中东和非洲市场分析和预测

  • 简介
    • 主要发现
  • 市场价值预测：按药物类别，2017-2031年
    • 苯基烷基胺
    • 苯妥英
    • 二氢吡啶
      • 第一代
      • 第二代
      • 第三代
  • 市场价值预测：按应用分类，2017-2031年
    • 高血压
    • 心绞痛
    • 心律失常
    • 肥厚型心肌病
    • 其他（雷诺氏病等）。
  • 市场价值预测：按给药途径，2017-2031年
    • 口服
    • 肠外
  • 市场价值预测：按分销渠道，2017-2031年
    • 医院药房
    • 零售药店
    • 网上药店
  • 市场价值预测：按国家/次区域划分，2017-2031年
    • 海湾合作委员会国家
    • 南非
    • 中东和非洲其他地区
  • 市场吸引力分析
    • 按药物类别
    • 按应用分类
    • 按给药途径分类
    • 按分销渠道
    • 按国家/次区域分类

第16章 ：竞争格局

  • 市场参与者 - 竞争矩阵（按公司的层级和规模划分）
  • 市场份额分析：按公司划分，2022年
  • 公司简介
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Bausch Health Company, Inc.
    • Novartis AG
    • AstraZeneca
    • Merck & Co. Inc.
    • GSK plc
    • Bayer AG
    • Sun Pharmaceutical Industries Ltd.
    • Daiichi Sankyo Company, Limited
Product Code: TMRGL35687

Calcium Channel Blockers Market - Scope of Report

TMR's report on the global Calcium Channel Blockers market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Calcium Channel Blockers market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Calcium Channel Blockers market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Calcium Channel Blockers market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Calcium Channel Blockers market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Calcium Channel Blockers market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Calcium Channel Blockers market.

The report delves into the competitive landscape of the global Calcium Channel Blockers market. Key players operating in the global Calcium Channel Blockers market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Calcium Channel Blockers market profiled in this report.

Key Questions Answered in Global Calcium Channel Blockers Market Report:

  • What is the sales/revenue generated by Calcium Channel Blockers across all regions during the forecast period?
  • What are the opportunities in the global Calcium Channel Blockers market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Calcium Channel Blockers Market - Research Objectives and Research Approach

The comprehensive report on the global Calcium Channel Blockers market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Calcium Channel Blockers market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Calcium Channel Blockers market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Calcium Channel Blockers Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Calcium Channel Blockers Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Disease Prevalence & Incidence Rate globally with key countries
  • 5.2. Key product/brand Analysis
  • 5.3. Pipeline Analysis
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Calcium Channel Blockers Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Drug Class, 2017-2031
    • 6.3.1. Phenylalkylamine
    • 6.3.2. Benzothizepine
    • 6.3.3. Dihydropyridine
      • 6.3.3.1. 1st Generation
      • 6.3.3.2. 2nd Generation
      • 6.3.3.3. 3rd Generation
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global Calcium Channel Blockers Market Analysis and Forecast, by Application

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Application, 2017-2031
    • 7.3.1. Hypertension
    • 7.3.2. Angina
    • 7.3.3. Arrhythmia
    • 7.3.4. Hypertrophic Cardiomyopathy
    • 7.3.5. Others (Raynaud's disease, etc.)
  • 7.4. Market Attractiveness Analysis, by Application

8. Global Calcium Channel Blockers Market Analysis and Forecast, by Route of Administration

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 8.3.1. Oral
    • 8.3.2. Parenteral
  • 8.4. Market Attractiveness Analysis, by Route of Administration

9. Global Calcium Channel Blockers Market Analysis and Forecast, by Distribution Channel

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Attractiveness Analysis, by Distribution Channel

10. Global Calcium Channel Blockers Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness Analysis, by Region

11. North America Calcium Channel Blockers Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2017-2031
    • 11.2.1. Phenylalkylamine
    • 11.2.2. Benzothizepine
    • 11.2.3. Dihydropyridine
      • 11.2.3.1. 1st Generation
      • 11.2.3.2. 2nd Generation
      • 11.2.3.3. 3rd Generation
  • 11.3. Market Value Forecast, by Application, 2017-2031
    • 11.3.1. Hypertension
    • 11.3.2. Angina
    • 11.3.3. Arrhythmia
    • 11.3.4. Hypertrophic Cardiomyopathy
    • 11.3.5. Others (Raynaud's disease, etc.)
  • 11.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 11.4.1. Oral
    • 11.4.2. Parenteral
  • 11.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.5.1. Hospital Pharmacies
    • 11.5.2. Retail Pharmacies
    • 11.5.3. Online Pharmacies
  • 11.6. Market Value Forecast, by Country, 2017-2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Drug Class
    • 11.7.2. By Application
    • 11.7.3. By Route of Administration
    • 11.7.4. By Distribution Channel
    • 11.7.5. By Country

12. Europe Calcium Channel Blockers Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2017-2031
    • 12.2.1. Phenylalkylamine
    • 12.2.2. Benzothizepine
    • 12.2.3. Dihydropyridine
      • 12.2.3.1. 1st Generation
      • 12.2.3.2. 2nd Generation
      • 12.2.3.3. 3rd Generation
  • 12.3. Market Value Forecast, by Application, 2017-2031
    • 12.3.1. Hypertension
    • 12.3.2. Angina
    • 12.3.3. Arrhythmia
    • 12.3.4. Hypertrophic Cardiomyopathy
    • 12.3.5. Others (Raynaud's disease, etc.)
  • 12.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 12.4.1. Oral
    • 12.4.2. Parenteral
  • 12.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.5.1. Hospital Pharmacies
    • 12.5.2. Retail Pharmacies
    • 12.5.3. Online Pharmacies
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Spain
    • 12.6.5. Italy
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Drug Class
    • 12.7.2. By Application
    • 12.7.3. By Route of Administration
    • 12.7.4. By Distribution Channel
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Calcium Channel Blockers Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2017-2031
    • 13.2.1. Phenylalkylamine
    • 13.2.2. Benzothizepine
    • 13.2.3. Dihydropyridine
      • 13.2.3.1. 1st Generation
      • 13.2.3.2. 2nd Generation
      • 13.2.3.3. 3rd Generation
  • 13.3. Market Value Forecast, by Application, 2017-2031
    • 13.3.1. Hypertension
    • 13.3.2. Angina
    • 13.3.3. Arrhythmia
    • 13.3.4. Hypertrophic Cardiomyopathy
    • 13.3.5. Others (Raynaud's disease, etc.)
  • 13.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 13.4.1. Oral
    • 13.4.2. Parenteral
  • 13.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.5.1. Hospital Pharmacies
    • 13.5.2. Retail Pharmacies
    • 13.5.3. Online Pharmacies
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Drug Class
    • 13.7.2. By Application
    • 13.7.3. By Route of Administration
    • 13.7.4. By Distribution Channel
    • 13.7.5. By Country/Sub-region

14. Latin America Calcium Channel Blockers Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Class, 2017-2031
    • 14.2.1. Phenylalkylamine
    • 14.2.2. Benzothizepine
    • 14.2.3. Dihydropyridine
      • 14.2.3.1. 1st Generation
      • 14.2.3.2. 2nd Generation
      • 14.2.3.3. 3rd Generation
  • 14.3. Market Value Forecast, by Application, 2017-2031
    • 14.3.1. Hypertension
    • 14.3.2. Angina
    • 14.3.3. Arrhythmia
    • 14.3.4. Hypertrophic Cardiomyopathy
    • 14.3.5. Others (Raynaud's disease, etc.)
  • 14.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 14.4.1. Oral
    • 14.4.2. Parenteral
  • 14.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.5.1. Hospital Pharmacies
    • 14.5.2. Retail Pharmacies
    • 14.5.3. Online Pharmacies
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Drug Class
    • 14.7.2. By Application
    • 14.7.3. By Route of Administration
    • 14.7.4. By Distribution Channel
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Calcium Channel Blockers Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Drug Class, 2017-2031
    • 15.2.1. Phenylalkylamine
    • 15.2.2. Benzothizepine
    • 15.2.3. Dihydropyridine
      • 15.2.3.1. 1st Generation
      • 15.2.3.2. 2nd Generation
      • 15.2.3.3. 3rd Generation
  • 15.3. Market Value Forecast, by Application, 2017-2031
    • 15.3.1. Hypertension
    • 15.3.2. Angina
    • 15.3.3. Arrhythmia
    • 15.3.4. Hypertrophic Cardiomyopathy
    • 15.3.5. Others (Raynaud's disease, etc.)
  • 15.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 15.4.1. Oral
    • 15.4.2. Parenteral
  • 15.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 15.5.1. Hospital Pharmacies
    • 15.5.2. Retail Pharmacies
    • 15.5.3. Online Pharmacies
  • 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Drug Class
    • 15.7.2. By Application
    • 15.7.3. By Route of Administration
    • 15.7.4. By Distribution Channel
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (by tier and size of companies)
  • 16.2. Market Share Analysis, by Company, 2022
  • 16.3. Company Profiles
    • 16.3.1. Pfizer, Inc.
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Teva Pharmaceutical Industries Ltd.
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Bausch Health Company, Inc.
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Novartis AG
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. AstraZeneca
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Merck & Co. Inc.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. GSK plc
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Bayer AG
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Sun Pharmaceutical Industries Ltd.
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. Daiichi Sankyo Company, Limited
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview

List of Tables

  • Table 01. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 02. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 03. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 04. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 05. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 06. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 07. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 08. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 09. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 10. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 11. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 12. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 13. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 14. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 15. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 16. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 17. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 18. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 19. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 20. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 21. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 22. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 23. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 24. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 25. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 26. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 27. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 28. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 29. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 30. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02. Global Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 03. Global Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 04. Global Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 05. Global Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 06. Global Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 07. Global Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 08. Global Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 09. Global Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 10. Global Calcium Channel Blockers Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 11. Global Calcium Channel Blockers Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 12. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 13. North America Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 14. North America Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 15. North America Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 16. North America Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 17. North America Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 18. North America Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 19. North America Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 20. North America Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 21. North America Calcium Channel Blockers Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 22. North America Calcium Channel Blockers Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 23. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 24. Europe Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 25. Europe Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 26. Europe Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 27. Europe Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 28. Europe Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 29. Europe Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 30. Europe Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 31. Europe Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 32. Europe Calcium Channel Blockers Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 33. Europe Calcium Channel Blockers Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 34. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 35. Asia Pacific Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 36. Asia Pacific Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 37. Asia Pacific Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 38. Asia Pacific Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 39. Asia Pacific Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 40. Asia Pacific Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 41. Asia Pacific Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 42. Asia Pacific Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 43. Asia Pacific Calcium Channel Blockers Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 44. Asia Pacific Calcium Channel Blockers Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 45. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 46. Latin America Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 47. Latin America Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 48. Latin America Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 49. Latin America Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 50. Latin America Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 51. Latin America Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 52. Latin America Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 53. Latin America Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 54. Latin America Calcium Channel Blockers Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 55. Latin America Calcium Channel Blockers Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 56. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 57. Middle East & Africa Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 58. Middle East & Africa Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 59. Middle East & Africa Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 60. Middle East & Africa Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 61. Middle East & Africa Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 62. Middle East & Africa Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 63. Middle East & Africa Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 64. Middle East & Africa Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 65. Middle East & Africa Calcium Channel Blockers Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 66. Middle East & Africa Calcium Channel Blockers Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 67. Global Calcium Channel Blockers Market Share Analysis, by Company, 2022